BioCentury
ARTICLE | Company News

Complete response for Novartis' Menveo in infants, toddlers

February 14, 2012 1:48 AM UTC

Novartis AG (NYSE:NVS; SIX:NOVN) said it received a complete response letter from FDA for an sBLA for Menveo to prevent invasive disease caused by Neisseria meningitides serogroups A, C, Y and W135 in infants and toddlers ages 2 months to 2 years. Novartis said FDA asked for additional data but the company did not disclose details. ...